Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald increased their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Trading Down 0.8 %

NASDAQ VNDA opened at $4.69 on Thursday. The stock has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $5.22. The company has a market capitalization of $272.95 million, a PE ratio of -58.63 and a beta of 0.77. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The company had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. As a group, sell-side analysts predict that Vanda Pharmaceuticals will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the business. Meeder Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the second quarter worth about $39,000. SageView Advisory Group LLC acquired a new position in shares of Vanda Pharmaceuticals during the first quarter worth about $34,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $40,000. SG Americas Securities LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $61,000. Finally, XTX Topco Ltd acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $75,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.